10-Q: PetMed Express Reports Q3 2025 Results: Sales Decline Amid Strategic Shift

PetMed Express reports a decrease in net sales for the quarter ended December 31, 2024, driven by a strategic reduction in advertising spend.

Summary

• PetMed Express, Inc. reported its financial results for the quarter ended December 31, 2024.
• Net sales decreased by 18.9% to $53.0 million compared to $65.3 million in the same quarter of the previous year.
• The decline in sales is attributed to a strategic reduction in gross advertising spend as the company resets its marketing foundation.
• Reorder sales decreased by 16.6% to $45.1 million, while new order sales decreased by 31.0% to $6.1 million.
• The company acquired approximately 63,000 new customers during the quarter, compared to 97,000 in the prior year.
• Cost of sales decreased by 19.7% to $38.1 million, and gross profit decreased by 16.6% to $14.9 million.
• General and administrative expenses decreased by 19.7% to $10.8 million, primarily due to lower stock-based compensation and payroll expenses.
• Advertising expenses decreased significantly by 48.2% to $3.0 million.
• The company reported a net loss of $707,000, or $0.03 per share, compared to a net loss of $2.0 million, or $0.10 per share, in the prior year's quarter.
• Adjusted EBITDA increased by 116% to $2.0 million from $0.9 million in the same period last year.
• For the nine months ended December 31, 2024, net sales decreased by 15.9% to $180.5 million compared to $214.6 million for the nine months ended December 31, 2023.
• The company reported net income of $5.4 million, or $0.26 per share, for the nine months ended December 31, 2024, compared to a net loss of $2.4 million, or $0.12 per share, for the nine months ended December 31, 2023.

Sentiment

Score: 5

Explanation: The report presents mixed signals. While the company is showing improved profitability through cost-cutting measures and increased efficiency, the decline in sales and customer acquisition is concerning. The material weaknesses in internal controls also raise concerns about the reliability of financial reporting.

Positives

• Adjusted EBITDA increased by 116% to $2.0 million for the quarter ended December 31, 2024.
• General and administrative expenses decreased by approximately $2.6 million, or 19.7%, to approximately $10.8 million for the quarter ended December 31, 2024.
• Cost of sales, as a percentage of sales, was 71.9% for the quarter ended December 31, 2024, compared to 72.6% for the quarter ended December 31, 2023.
• Recurring net sales, which includes AutoShip & Save subscriptions, and membership revenue, as a percentage of total gross sales was 56.2% for the most recent quarter ended December 31, 2024, up from 52.2% for the same period last year.

Negatives

• Net sales decreased by 18.9% to $53.0 million for the quarter ended December 31, 2024.
• Reorder sales decreased by 16.6% to $45.1 million for the quarter ended December 31, 2024.
• New order sales decreased by 31.0% to $6.1 million for the quarter ended December 31, 2024.
• The company acquired approximately 63,000 new customers during the quarter, compared to 97,000 in the prior year.
• The company reported a net loss of $707,000, or $0.03 per share, for the quarter ended December 31, 2024.

Risks

• Macroeconomic factors, including inflation and increased interest rates, may impact customer demand and the company's ability to forecast consumer spending patterns.
• Increased competition and consumer price sensitivity may adversely affect sales.
• The company identified material weaknesses in internal controls over financial reporting related to tax calculations and information technology general controls.

Future Outlook

The company expects macroeconomic factors to continue impacting operations for the remainder of fiscal 2025 and sales may be adversely affected due to increased competition and consumers giving more consideration to price.

Industry Context

The pet medication and supply industry is becoming increasingly competitive, with both online and brick-and-mortar retailers vying for market share. Companies like Chewy and Amazon are major competitors in the online space, while traditional veterinary clinics and pet stores also offer medications and supplies. PetMed Express is focusing on brand recognition and customer service to maintain its position in the market.

Comparison to Industry Standards

• Chewy, a major online pet retailer, reported net sales of $2.88 billion in its most recent quarter, demonstrating the scale of competition in the online pet market.
• Zoetis, a leading animal health company, reported revenue of $2.2 billion in its most recent quarter, highlighting the significant revenue potential in the animal health industry.
• PetMed Express's strategic shift to reduce advertising spend and focus on profitability aligns with a broader trend in the e-commerce industry, where companies are prioritizing sustainable growth over aggressive customer acquisition.

Management Changes

Corporate Governance

Legal Proceedings

• The company is involved in a legal proceeding in the Court of Common Pleas of Allegheny County, Pennsylvania, alleging violations of Pennsylvanias Unfair Trade Practices and Consumer Protection Law.

Related Party Transactions

• The Company entered into a master services agreement with Fabric, Inc., a privately-held company. Sandra Campos, Chief Executive Officer and President of the Company, is an equity-holder in Fabric and serves on the Board of Directors of Fabric.

Stakeholder Impact

• Shareholders are impacted by the decline in sales and the suspension of the quarterly dividend.
• Employees may be impacted by the company's efforts to improve the efficiency of its operations and align staffing needs.
• Customers may be impacted by changes in advertising and promotional strategies.

Next Steps

• The company will continue to monitor, evaluate, and manage its operating plans, forecasts, and liquidity.
• The company is implementing a remediation plan to address the material weaknesses in internal controls over financial reporting.

Key Dates